408 related articles for article (PubMed ID: 19364087)
1. Refractory Takayasu arteritis successfully treated with infliximab.
Maffei S; Di Renzo M; Santoro S; Puccetti L; Pasqui AL
Eur Rev Med Pharmacol Sci; 2009; 13(1):63-5. PubMed ID: 19364087
[TBL] [Abstract][Full Text] [Related]
2. Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature.
Comarmond C; Plaisier E; Dahan K; Mirault T; Emmerich J; Amoura Z; Cacoub P; Saadoun D
Autoimmun Rev; 2012 Jul; 11(9):678-84. PubMed ID: 22155781
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis.
Hoffman GS; Merkel PA; Brasington RD; Lenschow DJ; Liang P
Arthritis Rheum; 2004 Jul; 50(7):2296-304. PubMed ID: 15248230
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS
Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists.
Filocamo G; Buoncompagni A; Viola S; Loy A; Malattia C; Ravelli A; Martini A
J Pediatr; 2008 Sep; 153(3):432-4. PubMed ID: 18718263
[TBL] [Abstract][Full Text] [Related]
6. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup.
Schmidt J; Kermani TA; Bacani AK; Crowson CS; Matteson EL; Warrington KJ
Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1079-83. PubMed ID: 22328491
[TBL] [Abstract][Full Text] [Related]
8. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis.
Calderón R; Estrada S; Ramírez de la Piscina P; Salvador M; Zabaleta S; Enciso C; Delgado E; García-Campos F
Rev Esp Enferm Dig; 2010 Feb; 102(2):145-6. PubMed ID: 20361852
[No Abstract] [Full Text] [Related]
9. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?
Della Rossa A; Tavoni A; Merlini G; Baldini C; Sebastiani M; Lombardi M; Neglia D; Bombardieri S
Rheumatology (Oxford); 2005 Aug; 44(8):1074-5. PubMed ID: 15840604
[No Abstract] [Full Text] [Related]
10. Takayasu arteritis: anti-TNF therapy in a Brazilian setting.
Nunes G; Neves FS; Melo FM; de Castro GR; Zimmermann AF; Pereira IA
Rev Bras Reumatol; 2010; 50(3):291-8. PubMed ID: 21125165
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
12. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
13. Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab.
Tatò F; Rieger J; Hoffmann U
Int Angiol; 2005 Sep; 24(3):304-7. PubMed ID: 16158044
[TBL] [Abstract][Full Text] [Related]
14. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis].
Mocciaro F; Orlando A; Scimeca D; Cottone M
Recenti Prog Med; 2007 Nov; 98(11):560-4. PubMed ID: 18044405
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study.
Mekinian A; Néel A; Sibilia J; Cohen P; Connault J; Lambert M; Federici L; Berthier S; Fiessinger JN; Godeau B; Marie I; Guillevin L; Hamidou M; Fain O;
Rheumatology (Oxford); 2012 May; 51(5):882-6. PubMed ID: 22223706
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
Theodossiadis PG; Markomichelakis NN; Sfikakis PP
Retina; 2007; 27(4):399-413. PubMed ID: 17420690
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic hotline. Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report.
Baglieri F; Scuderi G
Dermatol Ther; 2010; 23(5):541-3. PubMed ID: 20868408
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids.
Rahimi R; Nikfar S; Abdollahi M
Med Sci Monit; 2007 Jul; 13(7):PI13-8. PubMed ID: 17599035
[TBL] [Abstract][Full Text] [Related]
19. Infliximab treatment for refractory Kawasaki syndrome.
Burns JC; Mason WH; Hauger SB; Janai H; Bastian JF; Wohrley JD; Balfour I; Shen CA; Michel ED; Shulman ST; Melish ME
J Pediatr; 2005 May; 146(5):662-7. PubMed ID: 15870671
[TBL] [Abstract][Full Text] [Related]
20. [Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis].
Ainsworth MA; Brynskov J
Ugeskr Laeger; 2007 Feb; 169(9):789-91. PubMed ID: 17355841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
